



Accreditation Information

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/ Nurse Practitioner

Rush University Medical Center designates this Live Activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)[™]. Physicians/ Physician Assistants/ Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Nurse

Rush University designates this Live Activity for a maximum of 5.0 nursing contact hour. This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Learning Objectives

This education programming is designed to provide oncology nurses the latest developments and critical insights into the management of lung cancer. This education will support the nurse professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application, which in turn may be helpful in the development and implementation collaborative care initiatives such as comprehensive patient management programs. To narrow the identified practice gap and underlying educational needs, the following objectives will be addressed within the proposed educational activities:

1. Differentiate among different lung cancer types including symptoms, diagnosis, staging, and prognosis, as well as implement a lung cancer screening program
2. Recognize the importance of genomic testing in guiding treatment decisions, and thereby facilitate patient education and implementation
3. Apply current treatment algorithms for NSCLC and SCL, including assisting patients through their treatment cycles via adherence, side effect management, and advocacy
4. Apply patient selection criteria, and side-effect management of novel targeted therapies and immune checkpoint inhibitors
5. Outline considerations and patient benefits for surgical management of lung cancer (thoracic surgery and stereotactic radiosurgery)

Target Audience: This live full day conference is specifically designed towards nurses treating patients with lung cancer in the Chicago vicinity.